Biogen
BIIB
Biogen (BIIB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $3.60
- EPS estimate
- $2.94
- EPS surprise
- +22.49%
- Revenue surprise
- +11.20%
- Revenue
- $2.7B
- Revenue estimate
- $2.5B
- Reported
- Jul 29, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $2.94 | $3.60 | +22.49% | $2.7B | SEC |
| Q1 2026 | Apr 29, 2026 | $3.08 | $3.57 | +15.77% | $2.5B | SEC |
| Q4 2025 | Feb 6, 2026 | $1.63 | $1.99 | +22.45% | $2.3B | SEC |
| Q3 2025 | Oct 30, 2025 | $3.88 | $4.81 | +23.89% | $2.5B | SEC |
| Q2 2025 | Jul 31, 2025 | $3.90 | $5.47 | +40.31% | $2.6B | SEC |
| Q1 2025 | May 1, 2025 | $2.90 | $3.02 | +4.16% | $2.4B | SEC |
| Q4 2024 | Feb 12, 2025 | $3.33 | $3.44 | +3.26% | $2.5B | SEC |
| Q3 2024 | Oct 30, 2024 | $3.77 | $4.08 | +8.15% | $2.5B | SEC |
| Q2 2024 | Aug 1, 2024 | $4.07 | $5.28 | +29.79% | $2.5B | SEC |
| Q1 2024 | Apr 24, 2024 | $3.47 | $3.67 | +5.78% | $2.3B | SEC |
| Q4 2023 | Feb 13, 2024 | $3.18 | $2.95 | −7.35% | $2.4B | SEC |
| Q3 2023 | Nov 8, 2023 | $3.97 | $4.36 | +9.73% | $2.5B | SEC |
| Q2 2023 | Jul 25, 2023 | $3.78 | $4.02 | +6.45% | $2.5B | SEC |
| Q1 2023 | Apr 25, 2023 | $3.28 | $3.40 | +3.72% | $2.5B | SEC |
| Q4 2022 | Feb 15, 2023 | $3.49 | $4.05 | +16.08% | $2.5B | SEC |
| Q3 2022 | Oct 25, 2022 | $4.13 | $4.77 | +15.61% | $2.5B | SEC |
| Q2 2022 | Jul 20, 2022 | $4.06 | $5.25 | +29.30% | $2.6B | SEC |
| Q1 2022 | May 3, 2022 | $4.34 | $3.62 | −16.59% | $2.5B | SEC |
| Q4 2021 | Feb 3, 2022 | $3.38 | $3.39 | +0.38% | $2.7B | SEC |
| Q3 2021 | Oct 20, 2021 | $4.09 | $4.77 | +16.73% | $2.8B | SEC |
Quarterly revenue
Frequently asked questions
When did Biogen (BIIB) last report earnings?
Biogen last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did BIIB beat earnings estimates?
Yes. Biogen reported EPS of $3.60 for Q2 2026 against a $2.94 estimate — a 22.49% beat.
How much revenue did BIIB report last quarter?
Biogen reported $2.7B in revenue for Q2 2026, against a consensus estimate of $2.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.